Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Aug 8;4(2):e00148.
doi: 10.1002/edm2.148. eCollection 2021 Apr.

Effect of 12-week continuous positive airway pressure therapy on glucose levels assessed by continuous glucose monitoring in people with type 2 diabetes and obstructive sleep apnoea; a randomized controlled trial

Anne Margareta Banghøj  1 , Christoffer Krogager  2   3   4 , Peter Lommer Kristensen  1 , Klavs Würgler Hansen  3 , Esben Laugesen  4 , Jesper Fleischer  5   6 , Simon Lebech Cichosz  7 , Per Løgstrup Poulsen  4   5 , Martin Glymer Kirkegaard  8 , Birger Thorsteinsson  1   9 , Lise Tarnow  6   10
Affiliations
Randomized Controlled Trial

Effect of 12-week continuous positive airway pressure therapy on glucose levels assessed by continuous glucose monitoring in people with type 2 diabetes and obstructive sleep apnoea; a randomized controlled trial

Anne Margareta Banghøj et al. Endocrinol Diabetes Metab. .

Abstract

Aim: Obstructive sleep apnoea (OSA) is frequent in type 2 diabetes (T2D). The aim was to investigate the effect of a 12-week treatment with continuous positive airway pressure (CPAP) on glycaemic control assessed by continuous glucose monitoring (CGM), HbA1c and fasting blood glucose in patients with T2D and newly detected OSA.

Methods: In a randomized controlled multicentre study, 72 participants with T2D and moderate to severe OSA (78% male, age 62 ± 7, AHI 35 ± 15) were recruited from outpatient clinics in three Danish hospitals and were randomized to CPAP intervention or control. The main outcome was glycaemic control assessed by 6 days CGM at baseline and after 12-week therapy, as well as by HbA1c and fasting blood glucose.

Results: No significant changes were found in average glucose levels, time in glucose range, time with hypoglycaemia, time with hyperglycaemia or coefficient of variability. HbA1c decreased 0.7 mmol/mol (0.07%; P = .8) in the CPAP group and increased 0.8 mmol/mol (0.08%; P = .6) in the control group (intergroup difference, P = .6). Fasting blood glucose increased by 0.2 mmol/L (P = .02) in the CPAP group and by 0.4 mmol/L (P = .01) in the control group (intergroup difference, P = .7). In a prespecified subgroup analysis comparing participants with high adherence (minimum usage of four hours/night for 70% of all nights) to CPAP to the control group, no significant changes were observed either, although these participants had a tendency towards better glycaemic indices.

Conclusions: CPAP treatment for 12 weeks does not significantly change glycaemic control in patients with type 2 diabetes and OSA.

Keywords: continuous glucose monitoring; continuous positive airway pressure; obstructive sleep apnoea; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Fleischer J. is the co‐inventor of Vagus™ device and holds stock in Medicus Engineering. No other author has reported conflicts of interest. ResMed Maribo have not had any influence on the design or conducting of the study, nor have they influenced the analysis of data or the manuscript.

Figures

Figure 1
Figure 1
Patient flow chart. The screening procedure was slightly different at the sites, since the Aarhus and Silkeborg investigators assessed the possible participants according to the in‐/exclusion criteria before sending out letters
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sleep‐related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep. Sleep. 1999;22:667‐689. - PubMed
    1. Sanchez AI, Martinez P, Miro E, Bardwell WA, Buela‐Casal G. CPAP and behavioral therapies in patients with obstructive sleep apnea: effects on daytime sleepiness, mood, and cognitive function. Sleep Med Rev. 2009;13:223‐233. - PubMed
    1. Banghoej AM, Nerild HH, Kristensen PL, et al. Obstructive sleep apnoea is frequent in patients with type 1 diabetes. J Diabetes Complications. 2017;31:156‐161. - PubMed
    1. Foster GD, Sanders MH, Millman R, et al. Obstructive sleep Apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32:1017‐1019. - PMC - PubMed
    1. Resnick HE, Redline S, Shahar E, et al. Diabetes and sleep disturbances: findings from the Sleep Heart Health Study. Diabetes Care. 2003;26:702‐709. - PubMed

Publication types